Evvy Raises $40M to Scale AI-Driven Vaginal Microbiome Testing
The women's health startup will expand its metagenomic sequencing platform into fertility and IVF care.
Women's health company Evvy has raised $40 million in an oversubscribed Series B funding round to expand its microbiome research into reproductive healthcare. The investment aims to integrate granular biological data into fertility and IVF treatments to reduce the prevalence of unexplained medical conditions.
The funding round was led by Catalio Capital Management, with participation from the U.S. Fertility Innovation Fund, Rethink Impact, and Labcorp Venture Fund. This latest injection of capital brings Evvy's total funding to nearly $60 million. The company intends to use the funds to scale EvvyAI, an artificial intelligence platform launched in May that translates complex microbiome data into real-time guidance and connects patients with clinicians.
The Shift to Precision Medicine
Founded in 2021 by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy was built to address a systemic lack of high-quality biological data regarding female bodies in precision medicine. While traditional diagnostics often rely on rudimentary criteria—such as the Amsel criteria for bacterial vaginosis—Evvy utilizes metagenomic sequencing (mNGS).
The company operates a CLIA-certified and CLEP-certified at-home test capable of analyzing more than 700 different bacteria and fungi. To date, Evvy has served over 100,000 patients and established partnerships with 3,000 healthcare practitioners. According to CEO and co-founder Priyanka Jain, precision medicine for women cannot be built on datasets that failed to adequately measure female biology from the start.
Impact on Reproductive Health
By developing one of the largest proprietary datasets on the vaginal microbiome, Evvy is targeting the gaps in reproductive healthcare. The company is specifically focusing on fertility and IVF, where it seeks to improve embryo transfer outcomes by modulating the microbiome. The goal is to move away from labeling certain infertility cases as "unexplained" and instead establish microbiome screening as a routine preventive benchmark, similar to the role of a Pap smear in cervical health.
Jacob Vogelstein, co-founder and managing partner at Catalio Capital, noted that the combination of proprietary data, clinical evidence, and a biomarker discovery engine provides a new foundation for precision healthcare for women.
Future Outlook
As Evvy scales its AI capabilities and expands its clinical reach, the industry will be watching whether its biomarker discovery engine can successfully standardize microbiome testing in fertility clinics. The company's ability to translate raw metagenomic data into actionable clinical outcomes remains the primary hurdle in moving these tests from a specialized tool to a routine standard of care.